XML 25 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Changes in Equity - USD ($)
$ in Millions
Total
Common Stock and Additional Paid-in Capital
Retained Earnings
Treasury Stock
Accumulated Other Comprehensive Income (Loss)
Non-controlling Interest
Balance at the beginning of the period at Dec. 31, 2021 $ 15,117 $ 6,438 $ 45,821 $ (30,463) $ (6,750) $ 71
Increase (decrease) in equity            
Net income (loss) 5,791 [1]   5,777     14
Other comprehensive income (loss), net of tax 69       77 (8)
Dividends declared (3,369)   (3,369)      
Stock-based compensation 262 262        
Reacquired stock (1,464)     (1,464)    
Dividend to noncontrolling interest (29)         (29)
Split-off of Food Safety business (1,988)     (1,988)    
Issuances pursuant to stock options and benefit plans 381   (279) 660    
Balance at the end of the period at Dec. 31, 2022 14,770 6,700 47,950 (33,255) (6,673) 48
Increase (decrease) in equity            
Net income (loss) (6,979) [1]   (6,995)     16
Other comprehensive income (loss), net of tax (105)       (105) 0
Dividends declared (3,311)   (3,311)      
Stock-based compensation 265 265        
Reacquired stock (33)     (33)    
Dividend to noncontrolling interest (3)         (3)
Issuances pursuant to stock options and benefit plans 264   (165) 429    
Balance at the end of the period at Dec. 31, 2023 4,868 6,965 37,479 (32,859) (6,778) 61
Increase (decrease) in equity            
Net income (loss) 4,188 [1]   4,173     15
Other comprehensive income (loss), net of tax 462       463 (1)
Solventum spin-off (2,167)   (2,751)   584  
Dividends declared (1,982)   (1,982)      
Stock-based compensation 273 273        
Reacquired stock (1,817)     (1,817)    
Dividend to noncontrolling interest (23)         (23)
Issuances pursuant to stock options and benefit plans 92   (122) 214    
Balance at the end of the period at Dec. 31, 2024 $ 3,894 $ 7,238 $ 36,797 $ (34,462) $ (5,731) $ 52
[1] The Consolidated Statements of Cash Flows include the results of continuing and discontinued operations and, therefore, also include cash and cash equivalents associated with Solventum through its April 2024 separation from 3M that were presented in current assets of discontinued operations in the 3M Consolidated Balance Sheet.